
Annual report 2024
added 03-21-2026
Nanobiotix S.A. Market Cap 2011-2026 | NBTX
As of April 07, 2026 Nanobiotix S.A. has a market cap of $ 286 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Nanobiotix S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 262 B | 405 M | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 262 B | 405 M | 131 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.36 | -2.52 % | $ 362 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
2.82 B | $ 20.25 | -0.54 % | $ 2.83 B | ||
|
Dyadic International
DYAI
|
31.5 M | $ 0.87 | 0.59 % | $ 31.5 M | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.78 | 4.83 % | $ 9.09 B | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
15.8 M | $ 2.6 | -2.26 % | $ 16.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Fate Therapeutics
FATE
|
187 M | $ 1.14 | -4.2 % | $ 135 M | ||
|
Forte Biosciences
FBRX
|
335 M | $ 26.44 | - | $ 342 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Fennec Pharmaceuticals
FENC
|
169 M | $ 6.16 | -4.05 % | $ 176 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Amicus Therapeutics
FOLD
|
4.43 B | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Fulcrum Therapeutics
FULC
|
539 K | $ 7.57 | -3.32 % | $ 480 K | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Galectin Therapeutics
GALT
|
178 M | $ 2.28 | -11.13 % | $ 146 M | ||
|
Gilead Sciences
GILD
|
183 B | $ 138.34 | -1.28 % | $ 172 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
1.25 M | $ 0.54 | 4.28 % | $ 503 K | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Genmab A/S
GMAB
|
25 B | $ 27.14 | -2.2 % | $ 17 B | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 88.2 | -3.37 % | $ 27.2 B | ||
|
Gossamer Bio
GOSS
|
107 M | $ 0.32 | -7.11 % | $ 73.1 M | ||
|
Coherus BioSciences
CHRS
|
226 M | $ 1.62 | -3.29 % | $ 190 M | ||
|
Grifols, S.A.
GRFS
|
8.42 B | $ 7.98 | -3.04 % | $ 6.83 B | ||
|
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 3.5 | -1.13 % | $ 236 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
GT Biopharma
GTBP
|
2.59 M | $ 0.41 | -8.56 % | $ 2.26 M | ||
|
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 316.69 | -4.13 % | $ 41.5 B | ||
|
Halozyme Therapeutics
HALO
|
9.66 B | $ 63.72 | 1.01 % | $ 7.64 B | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | ||
|
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 27.53 | -0.67 % | $ 1.58 B | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 4.53 | 1.0 % | $ 726 M | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M |